Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K5 | Q99683 | 2/20 | 0.66 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.56 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | POLB | P06746 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | RECQL | P46063 | 3/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.53 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.53 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14867614 | 1.00 | MAP3K5 (0.66) | MAP3K5PTPN12PTPN22MEN1ALDH1A1 | |
| SCHEMBL14859642 | 1.00 | MAP3K5 (0.66) | MAP3K5PTPN12PTPN22MEN1ALDH1A1 | |
| SCHEMBL3901300 | 0.90 | MAPT (0.67) | MAP3K5MEN1ALDH1A1POLBKMT2A | |
| SCHEMBL3901304 | 0.90 | MAPT (0.67) | MAP3K5MEN1ALDH1A1POLBKMT2A | |
| SCHEMBL46219 | 0.88 | ALDH1A1 (0.61) | MEN1ALDH1A1POLBKMT2AMAPT | |
| SCHEMBL14860651 | 0.87 | HIF1AN (0.64) | MAP3K5MEN1ALDH1A1POLBKMT2A | |
| SCHEMBL5991871 | 0.87 | HIF1AN (0.64) | MAP3K5MEN1ALDH1A1POLBKMT2A | |
| SCHEMBL3900339 | 0.87 | MAP3K5 (0.62) | MAP3K5MEN1ALDH1A1POLBKMT2A | |
| SCHEMBL5992796 | 0.87 | MAP3K5 (0.62) | MAP3K5MEN1ALDH1A1POLBKMT2A | |
| SCHEMBL14860649 | 0.87 | HIF1AN (0.64) | MAP3K5MEN1ALDH1A1POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210228548-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING, ALLEVIATING OR TREATING OSTEOARTHRITIS, CONTAINING RHODANINE DERIVATIVE AS ACTIVE INGREDIENT | AVIXGEN INC. (KR) | 2021-07-29 | — | — | US | claimed |
| EP-3827827-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING, ALLEVIATING OR TREATING OSTEOARTHRITIS, CONTAINING RHODANINE DERIVATIVE AS ACTIVE INGREDIENT | Avixgen Inc. (KR) | 2021-06-02 | — | — | EP | claimed |
| WO-2020022789-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING, ALLEVIATING OR TREATING OSTEOARTHRITIS, CONTAINING RHODANINE DERIVATIVE AS ACTIVE INGREDIENT | (주) 에빅스젠 | 2020-01-30 | — | — | WO | claimed |
| EP-2583969-A2 | NOVEL RHODANINE DERIVATIVES, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF AIDS CONTAINING THE RHODANINE DERIVATIVES AS ACTIVE INGREDIENTS | Avixgen Inc. (KR) | 2013-04-24 | — | — | EP | claimed |
| US-20130096125-A1 | NOVEL RHODANINE DERIVATIVES, METHOD FOR PREPARING SAME, AND PAHRMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF AIDS CONTAINING THE RHODANINE DERIVATIVES AS ACTIVE INGREDIENTS | AVIXGEN INC. (KR) | 2013-04-18 | — | — | US | claimed |
| US-20210228548-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING, ALLEVIATING OR TREATING OSTEOARTHRITIS, CONTAINING RHODANINE DERIVATIVE AS ACTIVE INGREDIENT | AVIXGEN INC. (KR) | 2021-07-29 | — | — | US | disclosed |
| EP-3827827-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING, ALLEVIATING OR TREATING OSTEOARTHRITIS, CONTAINING RHODANINE DERIVATIVE AS ACTIVE INGREDIENT | Avixgen Inc. (KR) | 2021-06-02 | — | — | EP | disclosed |
| WO-2020022789-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING, ALLEVIATING OR TREATING OSTEOARTHRITIS, CONTAINING RHODANINE DERIVATIVE AS ACTIVE INGREDIENT | (주) 에빅스젠 | 2020-01-30 | — | — | WO | disclosed |
| US-8759536-B2 | Rhodanine derivatives, method for preparing same, and pharmaceutical composition for the prevention or treatment of aids containing the rhodanine derivatives as active ingredients | AVIXGEN INC. (KR) | 2014-06-24 | — | — | US | disclosed |
| EP-2583969-A2 | NOVEL RHODANINE DERIVATIVES, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF AIDS CONTAINING THE RHODANINE DERIVATIVES AS ACTIVE INGREDIENTS | Avixgen Inc. (KR) | 2013-04-24 | — | — | EP | disclosed |
| US-20130096125-A1 | NOVEL RHODANINE DERIVATIVES, METHOD FOR PREPARING SAME, AND PAHRMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF AIDS CONTAINING THE RHODANINE DERIVATIVES AS ACTIVE INGREDIENTS | AVIXGEN INC. (KR) | 2013-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096125-A1 | NOVEL RHODANINE DERIVATIVES, METHOD FOR PREPARING SAME, AND PAHRMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF AIDS CONTAINING THE RHODANINE DERIVATIVES AS ACTIVE INGREDIENTS | LRAT, MRM1, ADH7 | MAP3K5 3482/4885PTPN12 4758/4885PTPN22 4685/4885 |
| US-20210228548-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING, ALLEVIATING OR TREATING OSTEOARTHRITIS, CONTAINING RHODANINE DERIVATIVE AS ACTIVE INGREDIENT | COL2A1, COL1A1, SYVN1 | MAP3K5 3896/4885PTPN12 3779/4885PTPN22 4224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.